Universal-Investment-Gesellschaft mbH har øget sin beholdning af aktier i SP Group A/S
Med henvisning til § 30 i Lov om kapitalmarkeder oplyses det hermed, at Universal-Investment-Gesellschaft mbH den 11. januar 2023 har meddelt SP Group A/S, at Universal-Investment-Gesellschaft mbH den 5. januar 2023 har øget sin beholdning af aktier med 11.569 stk. aktier og ejer nu i alt 636.231 stk. aktier a DKK 2,00 svarende til 5,09 % af aktiekapitalen og stemmerettighederne i SP Group A/S.
Vedhæftet fil
For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.
Information om GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg pressemeddelelser fra GlobeNewswire by notified
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra GlobeNewswire by notified
Genmab Announces Financial Results for the First Quarter of 20242.5.2024 17:01:34 CEST | Press release
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2024An additional Phase 3 clinical trial was initiated, evaluating epcoritamab in combination with rituximab and lenalidomide compared to chemoimmunotherapy in previously untreated follicular lymphoma The U.S. FDA accepted for Priority Review the sBLA seeking to convert the accelerated approval of Tivdak® (tisotumab vedotin-tftv) to full approval, for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after first-line therapyGenmab announced the decision of its arbitra
Sampo has received approval for its Group Partial Internal Model2.5.2024 17:00:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 2 May 2024 at 6:00 pm Sampo has received approval for itsGroup Partial Internal Model Sampo Group has today received approval for its Group Partial Internal Model (PIM) from the Swedish FSA (Finansinspektionen). The Group PIM recognises the risk profile of Sampo’s P&C operations better than the Standard Formula and as of 31 December 2023 it would have reduced the group-level solvency capital requirement (SCR) by EUR 0.3 billion. Sampo will apply the Group PIM in the second quarter and report its solvency based on this for the first time in its Half-Year Financial Report 2024. The Group remains committed to disciplined capital management and will, with the model in use, provide an update on capital allocation with its half-year 2024 results, in line with the communication provided at the Capital Markets Day on 6 March 2024. SAMPO PLC Investor Relations and Group Communications For further information, please contact: Sami Taipalus Head of Investor Relati
Fenix Outdoor: Fenix Outdoor International AG Press release AGM2.5.2024 17:00:00 CEST | Press release
Fenix Outdoors' Annual General Meeting in Solna on May 2, 2024 has been held The meeting resolved to approve the Annual Report for 2023the dividend 2023 to SEK 15.0 (15.0) per B-share and SEK 1.5 (1.5) per A-shareto grant discharge from liability for members of the Board and the Senior Executivesre-election of the Board; Mats Olsson, Ulf Gustafsson, Sebastian von Wallwitz, Susanne Dalsgaard Nordin and Rolf Schmidre-election of Martin Nordin as Chairman of the Boardre-election of Compensation committee; Ulf Gustafsson and Susanne Dalsgaard Nordinre-election of Dr. Philippe Meyer, lawyer, as Independent Proxy (for general meetings held in Switzerland) and Lars Sandberg, lawyer, as Independent Proxy (for General meetings held in Sweden), until the end of the next Annual General Meetingre-election of Ernst & Young Ltd, in Zurich as auditors, until the end of the next Annual General Meetingthe following compensations: Maximum EUR 1,900,000 as total compensation to the Board for the financ
Fenix Outdoor: Fenix Outdoor International AG Pressmeddelande Årsstämma2.5.2024 17:00:00 CEST | Pressemelding
Fenix Outdoors årsstämma i Solna den 2 maj 2024 har genomförts Stämman beslutade om att godkänna årsredovisningen för 2023utdelning för 2023 till 15 SEK (15) per B-aktie och 1,5 SEK (1,5) per A-aktieansvarsfrihet för styrelseledamöter och ledande befattningshavareomval av styrelse; Mats Olsson, Ulf Gustafsson, Sebastian von Wallwitz, Susanne Dalsgaard Nordin och Rolf Schmidomval av Martin Nordin som styrelsens ordförandeomval av ersättningskommitté; Ulf Gustafsson och Susanne Dalsgaard Nordinomval av Dr. Philippe Meyer, jurist, som oberoende ombud (för bolagsstämmor som hålls i Schweiz) och Lars Sandberg, advokat, som oberoende ombud (för bolagsstämmor som hålls i Sverige), fram till slutet av nästa årsstämmaomval av Ernst & Young Ltd, i Zürich som revisorer, fram till slutet av nästa årsstämmaföljande ersättningar: Maximalt EUR 1 900 000 som total ersättning till styrelsen för räkenskapsåret 2025.Maximalt EUR 3 500 000 som total fast ersättning till ledande befattningshavare för räken
Subsea 7 S.A. 2024 Annual General Meeting2.5.2024 16:35:23 CEST | Press release
Luxembourg – 2 May 2024 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY, the Company) today announced that, at the 2024 annual general meeting of shareholders on 2 May 2024, all resolutions were approved, including the payment of a dividend of NOK 6.00 per common share, to be paid in two equal instalments. The minutes of the annual general meeting which detail the resolutions passed and the result of the votes cast in relation to each resolution are attached and available at subsea7.com. ******************************************************************************* Subsea7 creates sustainable value by delivering the offshore energy transition solutions the world needs. Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62. ******************************************************************************* Contact for investment community enquiries: Katherine Tonks Investor Relations Director Tel +44 20 8210 5568 ir@subsea7.com This information is subject to t